MX2019001860A - Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab. - Google Patents

Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.

Info

Publication number
MX2019001860A
MX2019001860A MX2019001860A MX2019001860A MX2019001860A MX 2019001860 A MX2019001860 A MX 2019001860A MX 2019001860 A MX2019001860 A MX 2019001860A MX 2019001860 A MX2019001860 A MX 2019001860A MX 2019001860 A MX2019001860 A MX 2019001860A
Authority
MX
Mexico
Prior art keywords
ofatumumab
multiple sclerosis
treating multiple
regimens
methods
Prior art date
Application number
MX2019001860A
Other languages
English (en)
Inventor
Wallström Erik
SAVELIEVA PRAZ Marina
Jonas Kakarieka Weisskopf Algirdas
Michael Kahn Joseph
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019001860A publication Critical patent/MX2019001860A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Abstract

La divulgación está dirigida a regímenes de tratamiento para tratar la esclerosis múltiple (MS). Estos métodos utilizan la administración de ofatumumab, un anticuerpo monoclonal anti-CD20, al paciente durante un régimen de dosis de carga y un régimen de mantenimiento.
MX2019001860A 2016-08-15 2017-08-11 Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab. MX2019001860A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374986P 2016-08-15 2016-08-15
PCT/IB2017/054909 WO2018033841A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Publications (1)

Publication Number Publication Date
MX2019001860A true MX2019001860A (es) 2019-07-08

Family

ID=59901554

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001860A MX2019001860A (es) 2016-08-15 2017-08-11 Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.

Country Status (24)

Country Link
US (2) US11161909B2 (es)
EP (3) EP4252847A3 (es)
JP (2) JP6851391B2 (es)
KR (2) KR20200136503A (es)
CN (1) CN109641965A (es)
AU (2) AU2017311664B2 (es)
CA (2) CA3030530C (es)
CY (1) CY1123350T1 (es)
DE (1) DE202017007542U1 (es)
DK (2) DK3497132T3 (es)
ES (2) ES2821924T3 (es)
FI (1) FI3733712T3 (es)
HR (2) HRP20230894T1 (es)
HU (2) HUE063625T2 (es)
IL (3) IL302488A (es)
LT (2) LT3733712T (es)
MX (1) MX2019001860A (es)
PL (2) PL3497132T3 (es)
PT (2) PT3497132T (es)
RS (2) RS60807B1 (es)
RU (1) RU2749951C2 (es)
SI (2) SI3733712T1 (es)
TW (1) TWI752995B (es)
WO (1) WO2018033841A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641965A (zh) * 2016-08-15 2019-04-16 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法
AU2020347474A1 (en) * 2019-09-11 2022-04-07 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
CA3150947A1 (en) 2019-09-11 2021-03-18 Novartis Ag Treatment of rms by switching therapy
EP4323000A1 (en) * 2021-04-14 2024-02-21 Novartis AG Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2012096924A1 (en) * 2011-01-10 2012-07-19 Glaxo Group Limited Novel uses
US9409976B2 (en) * 2012-02-08 2016-08-09 Igm Biosciences, Inc. CDIM binding proteins and uses thereof
BR112015002590A2 (pt) * 2012-08-10 2019-08-06 Boehringer Ingelheim Int compostos heteroaromáticos como inibidores de tirosina cinase de bruton (btk)
CN107407677B (zh) * 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
CN109641965A (zh) * 2016-08-15 2019-04-16 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法

Also Published As

Publication number Publication date
PT3733712T (pt) 2023-08-31
RU2021105514A3 (es) 2022-02-08
TWI752995B (zh) 2022-01-21
RU2021105514A (ru) 2021-04-19
RU2019107146A (ru) 2020-09-15
KR20190038914A (ko) 2019-04-09
SI3733712T1 (sl) 2023-12-29
DK3497132T3 (da) 2020-09-07
WO2018033841A1 (en) 2018-02-22
CN109641965A (zh) 2019-04-16
CA3030530A1 (en) 2018-02-22
AU2017311664A1 (en) 2019-01-31
EP4252847A2 (en) 2023-10-04
EP3497132A1 (en) 2019-06-19
US11161909B2 (en) 2021-11-02
RU2749951C2 (ru) 2021-06-21
ES2954259T3 (es) 2023-11-21
EP3497132B1 (en) 2020-06-24
JP7198786B2 (ja) 2023-01-04
EP3733712B1 (en) 2023-05-24
IL276890A (en) 2020-10-29
DK3733712T3 (da) 2023-08-21
SI3497132T1 (sl) 2020-10-30
LT3497132T (lt) 2020-10-12
US20190177424A1 (en) 2019-06-13
HUE063625T2 (hu) 2024-01-28
KR20200136503A (ko) 2020-12-07
HUE051948T2 (hu) 2021-03-29
ES2821924T3 (es) 2021-04-28
LT3733712T (lt) 2023-09-11
RS64541B1 (sr) 2023-09-29
RU2019107146A3 (es) 2020-09-15
FI3733712T3 (fi) 2023-08-22
EP3733712A1 (en) 2020-11-04
IL276890B2 (en) 2023-10-01
IL276890B1 (en) 2023-06-01
AU2017311664B2 (en) 2020-01-02
IL302488A (en) 2023-06-01
AU2020201112A1 (en) 2020-03-05
CY1123350T1 (el) 2021-12-31
HRP20201388T1 (hr) 2020-11-27
DE202017007542U1 (de) 2022-07-19
JP2019511506A (ja) 2019-04-25
AU2020201112B2 (en) 2021-07-22
JP2020100630A (ja) 2020-07-02
JP6851391B2 (ja) 2021-03-31
PT3497132T (pt) 2020-09-25
CA3030530C (en) 2021-02-23
PL3733712T3 (pl) 2023-10-16
RS60807B1 (sr) 2020-10-30
TW201808333A (zh) 2018-03-16
US20220081488A1 (en) 2022-03-17
EP4252847A3 (en) 2023-11-15
CA3101514A1 (en) 2018-02-22
PL3497132T3 (pl) 2020-11-30
IL264804B (en) 2020-09-30
HRP20230894T1 (hr) 2023-11-24

Similar Documents

Publication Publication Date Title
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MX2019001860A (es) Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
EA201792209A1 (ru) Схема введения пропущенных доз инъекционных сложных эфиров палиперидона длительного действия
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
MX2022015115A (es) Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.
MX2017000366A (es) Terapia de combinacion para el cancer.
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
MX2018002554A (es) Combinaciones de inhibidores de btk para tratar mieloma multiple.
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
PH12017500275A1 (en) Methods of treating depression using nmda modulators
MX2017014396A (es) Tratamiento de mieloma multiple.
MX2021010313A (es) Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
CO2022009433A2 (es) Uso de isatuximab para el tratamiento del mieloma múltiple recidivante y/o refractario
MX2021012848A (es) Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.
MX2021002647A (es) Metodos de tratamiento de la psoriasis.
MX2023007405A (es) Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple.